Is Asahi Kasei profitable in 2026?

Yes. For FY2025 (ended March 31, 2026), Asahi Kasei reported net sales of ¥3,074.5 billion, operating income of ¥231.2 billion (up 9.1%, a record for the second straight year), and net income of ¥158.8 billion, up 17.6% year over year, per its May 12, 2026 results filing.

Is Asahi Kasei doing layoffs?

No mass layoffs are confirmed, but headcount is flat to slightly declining: company profile lists 47,895 consolidated employees as of March 31, 2026, while Revelio Labs estimated 47,652 employees in December 2025 (down 0.4% YoY) with active job postings down 46.2% in 2025, alongside restructuring exits of several Material-sector product lines.

Could AI replace Asahi Kasei's business?

Unlikely. Asahi Kasei's revenue comes from physical chemical plants, FDA-regulated pharma, medical devices, and construction, not software. AI is used internally as an R&D accelerant (e.g., its MI-Hub platform and a 2023 NEC materials-informatics partnership) rather than as a threat replacing its manufacturing or regulatory moats.

Who is Asahi Kasei's biggest competitor?

In battery separators, China's SEMCORP Group overtook Asahi Kasei as the world's largest separator-film supplier by volume as of 2019, per Chemical & Engineering News (2025-10-29). Broader chemicals peers include Shin-Etsu, Mitsubishi Chemical, Toray, Sumitomo Chemical, and Resonac Holdings.

Is Asahi Kasei a safe company to join?

Structurally yes: FY2025 revenue was ¥3,074.5 billion with record operating income for a second straight year (2026-05-12 filing) and a ¥1 trillion investment plan through FY2027. Risk depends on division: commodity Material lines like MMA/PMMA and SB latex were discontinued in May 2025 with about ¥25 billion in restructuring costs, while Healthcare and AI/semiconductor materials are funded growth areas.

Who owns Asahi Kasei?

Asahi Kasei Corporation is an independent, publicly traded company on the Tokyo Stock Exchange (ticker 3407), a constituent of TOPIX 100 and Nikkei 225, with no parent company. Market cap was reported around ¥2.48 trillion as of mid-2026 (gurufocus.com).

Manufacturing companies · Japan

Asahi Kasei Corporation

asahi-kasei.com ↗

Diversified Japanese maker of chemicals, materials, homes, and healthcare products.

Hard to displace

Assessed 25 July 2026 · Evidence as of 25 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 25 July 2026 · Checkable from Q4 2026 · Every call on the record Checkpoint: FDA PDUFA decision on pritelivir

The call

A century-old conglomerate posting record profits while betting growth on healthcare and AI-adjacent materials, even as commodity chemical lines get trimmed and battery separator pricing tightens.

Asahi Kasei makes chemicals, plastics, building materials, and healthcare products across dozens of factories worldwide. It is hard to replace because it owns specialized factories, holds FDA approvals, and has long-term contracts with big manufacturers, but some of its older plastic lines face real price competition from Chinese makers and South Korean rivals like SEMCORP. The key thing that could change the picture is whether Asahi Kasei can grow fast enough in battery separators and semiconductor materials to offset profits it is losing by exiting older, cheaper plastic products.

Why

AI pressure: None apparent. AI is a demand driver here: semiconductor-packaging and battery materials feed AI hardware buildout, not a threat to the business. Could AI do the core job? Unlikely.

Bigger players: SEMCORP and Chinese/Korean battery separator makers. Cheaper Chinese and Korean separator supply is pressuring Hipore/Celgard pricing in the battery materials business. Could a giant copy it? No, they are blocked.

What protects it. Process patents, FDA approvals, decades-long supply contracts, and spread across pharma, housing, and specialty chemicals so no single loss sinks it.

What would change this call

Pritelivir FDA PDUFA decision, Q4 2026. Rejection would undercut the Healthcare growth pillar meant to offset Material segment weakness.
Material segment margin trend at Q1 FY2027 earnings, July 30 2026. Further compression would confirm battery separator and commodity chemical share loss to Asian rivals.
Mizushima Works restructuring charges vs FY2030 guidance. Charges exceeding guidance would show exit of styrene/acrylonitrile lines is costlier than planned.

Key numbers

FY2025 net sales ¥3,074.5 billion, up 1.2% (2026-03-31)
FY2025 operating income ¥231.2B, record high (2026-03-31)
FY2027 operating income target ¥270 billion (2026-06-23)

Named risks

Chinese and Korean battery separator competitors pressuring pricing and share in a named growth pillar. Severity: high
FDA decision on pritelivir (Aicuris asset) due Q4 2026 could impair value of recent ~€780M acquisition if rejected. Severity: medium
Mizushima Works line exits and Material-sector restructuring through FY2030 may generate further one-time charges. Severity: medium
North American housing demand softness pressuring the Homes segment. Severity: medium
Headcount stagnation and declining job postings (-46.2% in 2025 per Revelio Labs) amid negative employee sentiment. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
SEMCORP Group	losing to	Overtook Asahi Kasei as world's largest battery separator supplier by volume as of 2019
Toray Industries	contesting	Toray pulling back from separator investment while Asahi Kasei doubles down, per Oct 2025 report
Shin-Etsu Chemical	contesting	Listed alongside Asahi Kasei as core diversified chemicals peer in analyst comparison sets (2026)
Mitsubishi Chemical Group	contesting	Joint AI-prediction materials research partner and sector competitor (2021 project)
Resonac Holdings	contesting	Named as Japanese chemicals competitor in 2026 analyst peer sets

Questions people ask

Is Asahi Kasei profitable in 2026?: Yes. For FY2025 (ended March 31, 2026), Asahi Kasei reported net sales of ¥3,074.5 billion, operating income of ¥231.2 billion (up 9.1%, a record for the second straight year), and net income of ¥158.8 billion, up 17.6% year over year, per its May 12, 2026 results filing.
Is Asahi Kasei doing layoffs?: No mass layoffs are confirmed, but headcount is flat to slightly declining: company profile lists 47,895 consolidated employees as of March 31, 2026, while Revelio Labs estimated 47,652 employees in December 2025 (down 0.4% YoY) with active job postings down 46.2% in 2025, alongside restructuring exits of several Material-sector product lines.
Could AI replace Asahi Kasei's business?: Unlikely. Asahi Kasei's revenue comes from physical chemical plants, FDA-regulated pharma, medical devices, and construction, not software. AI is used internally as an R&D accelerant (e.g., its MI-Hub platform and a 2023 NEC materials-informatics partnership) rather than as a threat replacing its manufacturing or regulatory moats.
Who is Asahi Kasei's biggest competitor?: In battery separators, China's SEMCORP Group overtook Asahi Kasei as the world's largest separator-film supplier by volume as of 2019, per Chemical & Engineering News (2025-10-29). Broader chemicals peers include Shin-Etsu, Mitsubishi Chemical, Toray, Sumitomo Chemical, and Resonac Holdings.
Is Asahi Kasei a safe company to join?: Structurally yes: FY2025 revenue was ¥3,074.5 billion with record operating income for a second straight year (2026-05-12 filing) and a ¥1 trillion investment plan through FY2027. Risk depends on division: commodity Material lines like MMA/PMMA and SB latex were discontinued in May 2025 with about ¥25 billion in restructuring costs, while Healthcare and AI/semiconductor materials are funded growth areas.
Who owns Asahi Kasei?: Asahi Kasei Corporation is an independent, publicly traded company on the Tokyo Stock Exchange (ticker 3407), a constituent of TOPIX 100 and Nikkei 225, with no parent company. Market cap was reported around ¥2.48 trillion as of mid-2026 (gurufocus.com).

Timeline

2026-05-12FY2025 results: net sales ¥3,074.5B, operating income ¥231.2B (record, +9.1%), net income ¥158.8B (+17.6%)
2026-05-12Announced plan to exit styrene and acrylonitrile lines at Mizushima Works by FY2030
2026-04-20Completed ~€780M acquisition of German biopharma Aicuris via subsidiary Veloxis Pharmaceuticals
2026-02-26Announced plan to acquire Aicuris, adding pritelivir asset under FDA Priority Review
2025-12-01Closed divestiture of Daramic lead-acid battery separator business to Kingswood Capital Management
2025-07-30Signed Hipore lithium-ion battery separator supply agreement with Toyota Tsusho for North America
2025-05-27Announced discontinuation of MMA, CHMA, PMMA resin and SB latex businesses, ~¥25B restructuring cost
2025-04-10Launched Trailblaze Together medium-term plan (FY2025-2027), targeting ¥1T investment

Revision history

25 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

BHP Group Energy Transfer EOG Resources